Immediate zoledronic acid treatment better than delayed in women receiving letrozole
the ONA take:
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer and these differences were maintained at 5 years, a study published in the American Cancer Society journal Cancer has found.
Because it is known that postmenopausal women with breast cancer receiving aromatase inhibitors are at a higher risk for bone loss, researchers sought to compare the impact of immediate versus delayed treatment with zoledronic acid on bone loss.
Researchers analyzed data from 551 postmenopausal women who had received tamoxifen and were now receiving daily letrozole. Patients were randomly assigned 1:1 to upfront or delayed zoledronic acid 4mg IV every 6 months.
Results showed that the incidence of a 5% decrease in the total lumbar spine bone density was 10.2% and 41.2% in the upfront and delayed groups, respectively (P < 0.0001), suggesting that immediate treatment prevented bone loss moreso than delayed treatment at 5 years; however, researchers found that the incidence of osteoporosis or fractures was not significantly different between treatment arms.
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in breast cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|